3 documents found, page 1 of 1
Nivolumab-Induced Seronegative Encephalitis
Cabral, G; Ladeira, F; Gil, NImmune checkpoint inhibitors (ICIs) have emerged as a new therapeutic tool for numerous types of cancer. Neurological complications have been reported in 1% of patients who have undergone checkpoint inhibition therapy. ICIs-induced encephalitides occur in 0.1-0.2% of patients within weeks after ICIs initiation; are usually seronegative and have nonspecific changes on imaging, CSF and electroencephalogram (EEG) ...
Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in ...
Figueiredo, A; Almeida, M A; Almodovar, M T; Alves, P; Araújo, A; Araújo, D; Barata, F; Barradas, L; Barroso, A; Brito, U; Camacho, E; Canário, DOBJECTIVE: The main aim of the study was to evaluate the efficacy and safety profile of Nivolumab, an immune-checkpoint-inhibitor antibody, in advanced, previously treated, Non-Small Cell Lung Cancer (NSCLC) patients, in a real world setting. METHODS: We performed a retrospective, multicentre data analysis of patients who were included in the Portuguese Nivolumab Expanded Access Program (EAP). Eligibility crite...
Use of antipsychotic drugs. A multicentric study of inpatients with acute psych...
Xavier, Miguel; Barahona, B; Batalim, P; Matos, Cabeças J; Domingos, E; Freitas, F; Gamito, A; Gil, N; Laureano, C; Leuschner, A; Lopes, J; Luís, AWith the objective of determining the pattern and decision making process in using antipsychotic drugs in patients admitted to hospital for acute psychotic disorder we have made a retrospective analysis in 244 in-patients in 7 hospitals for mental disorders. We have selected two groups, IM and PO, that in the first three days of internment have received either intravenous antipsychotic medication or oral medica...